Seahorse Bioscience , a biomedical instrument company based in Billerica, MA, announced today that it has closed a $5 million Series D financing round. Participants in the round include return investors Commonwealth Capital Ventures, Rock Maple Ventures, and Life Sciences Partners, and new investors FLIR Systems, Oxford Bioscience Partners, Healthcare Ventures, New Science Ventures, and HLM Venture Partners. Seahorse will use the money to beef up international sales, marketing, and manufacturing of its XF series of instruments, which measure energy in cells are used as a tool for cancer research.
Author: Howard Lovy
Howard Lovy is a veteran journalist who has focused primarily on technology, science and innovation during the past decade.
In 2001, he helped launch Small Times Magazine, a nanotech publication based in Ann Arbor, MI, where he built the freelance team and worked closely with writers to set the tone and style for an emerging sector that had never before been covered from a business perspective. Lovy's work at Small Times, and on one of the first nanotechnology-themed blogs, helped him earn a reputation for making complex subjects understandable, interesting, and even entertaining for a broad audience. It also earned him the 2004 Prize in Communication from the Foresight Institute, a nanotech think tank.
In his freelance work, Lovy covers nanotechnology in addition to technological innovation in Michigan with an emphasis on efforts to survive and retool in the state's post-automotive age. Lovy's work has appeared in many publications, including Wired News, Salon.com, the Wall Street Journal, The Detroit News, The Scientist, the Forbes/Wolfe Nanotech Report, Michigan Messenger, and the Ann Arbor Chronicle.
View all posts by Howard Lovy